When the patients with chronic renal failure need drug therapy,we must select the appropriate drugs and adjust the drug delivery methods and dosage according to the renal function of these patients,at the same time we have to consider the factors such as age,sex,weight,combined medication,damage of other organs and so on,the therapeutic drug concentration monitoring should be paid attention to.For patients with blood purification,if the drug mainly removed by the kidneys,adjustments of drug administration must be based on the molecular weight of drug,volume of distribution,protein binding rate,mode of dialysis and hemodialyzer.We must ensure the drug efficacy and reduce the adverse reactions of drugs at the same time in the patients of renal insufficiency.

Enterovirus A, Human ; Enterovirus Infections ; pathology ; Female ; Hemorrhage ; etiology ; virology ; Humans ; Infant ; Male ; Pulmonary Edema ; etiology ; virology

Asian Continental Ancestry Group ; China ; Humans ; Sepsis ; Terminology as Topic ; Translations

Anti-Bacterial Agents ; therapeutic use ; Child ; Humans ; Practice Guidelines as Topic ; Sepsis ; classification ; complications ; diagnosis ; drug therapy ; physiopathology

Objective To explore the clinical curative effect of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease.Methods 128 patients with non-alcoholic fatty liver disease in our hospital were selected, and they were randomly divided into control group and research group,64 cases in each group.The control group received ursodeoxycholic acid capsules, the research group received reduced glutathione tablet on the basis of ursodeoxycholic acid capsules,the two groups received treatment of two periods, each period had one and half months.The liver function and blood lipid were detected and compared between the two groups.Results The total clinical effective rate of the research group was 93.75%, which of the control group was 68.75% (x2=20.5,P=0.000),the difference was statistically significant.After treatment, liver function (ALT, AST, TBIL, GGT and ALP) and lipid levels (TG and CHO) of the two groups were improved significantly[the control group:before treatment (138.75±30.63) IU/L,(161.72±55.61) IU/L,(183.65±58.47) μmol/L,(213.65±40.35) IU/L,(82.38±23.15) IU/L,(2.85±0.77) μmol/L,(6.45±0.37) μmol/L, after treatment (66.38±26.31) IU/L,(65.39±22.15) IU/L,(92.38±36.15) μmol/L,(99.68±36.72) IU/L,(30.23±10.36) IU/L,(1.92±0.58) mol/L,(5.39±0.53) μmol/L;the research group before treatment (141.25±32.53) IU/L,(157.56±58.31) IU/L,(190.23±51.27) μmol/L,(223.72±43.18) IU/L,(80.86±21.85) IU/L,(2.92±0.73) μmol/L,(6.43±0.82) μmol/L, after treatment (37.64±11.25) IU/L,(36.25±11.83) IU/L,(47.67±8.32) μmol/L,(70.52±26.31) IU/L,(16.69±7.32) IU/L,(1.32±0.63) μmol/L,(4.31±0.63) μmol/L],the differences were statistically significant(the control group :t=14.3,12.9,10.6,16.7,16.4,7.7,13.1,all P<0.01;the research group:t=24.1,25.4,21.9,24.2,16.1,13.3,16.4,all P<0.01),but these indicators of the research group were improved significantly better than those of the control group, the differences were statistically significant(t=8.0,9.3,9.6,8.5,8.5,5.6,10.5;all P<0.01).Conclusion The clinical curative effect of research group is distinct, safe and has no obvious adverse reactions, which is worthy of clinical application.

Non-myeloablative allogeneic hematopoietic stem cell transplantation has been extensively applied in patients with hematologic malignancies who are ineligible for conventional hematopoietic stem cell transplantation because of age or medical comorbidities. Non-myeloablative regimens lead to an initial state of mixed hematopoietic chimerism which can produce a marked effect of graft versus tumor to treat the diseases. Compared with the conventional hematopoietic stem cell transplantation, non-myeloablative allogeneic hematopoietic stem cell transplantation has a lower transplant-related mortality and incidence rate of graft-versus-host disease. The improvement of non-myeloablative regimens and the prophylaxis of diseases associated with transplantation can improve the therapeutic efficacy. Though many therapies have been introduced and proved to be successful in animal models, we still need to investigate the research trend and the problem on human body.

Clinical research initiated by researchers is one of the important means to promote new understanding of drugs and treatment methods.At this stage,the clinical researches initiated by the researchers frequently appear all kinds of irregularities.In order to solve out this problem,the paper points out suggestions about strengtheningself-discipline of researchers,self-regulation of conscience,and self-responsibility of carefulness.Meanwhile,it is also important to abide by the relevant ethical codes and consciously accept the third party supervision of IRB.Joint efforts should be made to protect safety and rights of human subjects.

Systemic Inflammatory Response Syndrome ; virology ; Virus Diseases

To explore the relationship between clinical findings and pathological changes of IgA nephropathy (IgAN), 37 children with IgAN were undertaken clinical classification and renal-pathological comparison including glomerulus change, renal tubule-interstitial change and immunopathology. The results showed that there were 18 (49%) cases with hematuria, 14 (38%) cases with nephrotic syndrome, 3(8%) cases with both of hematuria and proteineuria, and 2 (5%) cases with nephritic syndrome in the clinical classification. 54% of cases with glomerulus changes was as class III. No significant relationship was found between clinical classification and glomerulus changes. There were 24 cases with renal-tubule interstitial changes and 7 cases with hematuria. 43% of them were classified as class I and 57% as class II.All cases with nephrotic syn-drome developed renal tubule-interstitial change. 78% (11 cases) of them were as class II and 22% (3 cases) as class III. Besides, 2 of 3 cases with both of hematuria and proteineuria and 1 of 2 cases with nephritic syndrome also manifested renal tubule-interstitial change. There were four phenotypes were observed in immunopathology including 16 cases of them as IgA, 6 cases as IgAG, 10 cases as IgAM and 5 cases as IgAGM, respectively. 66% of cases with hematuria was found as IgA and 50% of cases with nephrotic syndrome as IgAM. It is concluded that hematuria can be a main clinical finding in both of IgAN and nephrotic syndrome. Glomerulus changes is usually not correlated with clinical classification. There is a significant renal tubule-interstitial change in cases with nephrotic syndrome. Hematuria is usually as IgA and nephrotic syndrome as IgAM in immunopathology.